Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 7/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9982871 | 0.76 | KMT2A (0.43) | LMNAMAPK1MEN1KMT2ANPC1 | |
| SCHEMBL9982481 | 0.76 | DHFR (0.44) | OPRM1OPRK1OGFRL1OPRD1NPSR1 | |
| SCHEMBL12598295 | 0.75 | BRD4 (0.63) | OPRM1OPRK1OGFRL1OPRD1LMNA | |
| SCHEMBL14827783 | 0.73 | THRB (0.42) | OPRM1OPRK1OGFRL1OPRD1LMNA | |
| SCHEMBL9982909 | 0.73 | GAA (0.43) | LMNANPSR1MAPK1MEN1KMT2A | |
| SCHEMBL12067255 | 0.72 | C5AR1 (0.49) | OPRM1OPRK1OPRD1LMNAOPRL1 | |
| SCHEMBL8792880 | 0.72 | POLB (0.52) | LMNANPSR1MAPK1MEN1KMT2A | |
| SCHEMBL14826124 | 0.71 | OGFRL1 (0.47) | OPRM1OPRK1OGFRL1OPRD1LMNA | |
| SCHEMBL8630899 | 0.71 | OPRM1 (0.49) | OPRM1OPRK1OGFRL1OPRD1OPRL1 | |
| SCHEMBL9982687 | 0.70 | OPRM1 (0.60) | OPRM1OPRK1OGFRL1OPRD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582681-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | OPRM1 956/4885OPRK1 610/4885OGFRL1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.